论文部分内容阅读
目的通过对中药“骨痿方”治疗新疆地区维吾尔族女性,脾肾两虚兼血瘀型老年性骨质疏松症的研究,观察治疗前后生化骨特异性碱性磷酸酶(BAP)、抗酒石酸酸性磷酸酶(TRACP 5b)的变化。方法通过收集符合诊断标准的患者60例,按随机数字表分成治疗组30例、对照组30例,比较两组治疗前对所有的患者骨密度检测、骨特异性碱性磷酸酶(BAP)、抗酒石酸酸性磷酸酶(TRACP5b)的变化。结果统计结果表明,治疗后治疗组与对照组骨特异性指标比较,治疗组与对照组Trap 5b没有明显差别(P=0.49>0.05),而BAP治疗前后,二者有统计学差异(P=0.02<0.05);治疗组治愈率、总有效率优于对照组,二者有统计学差异(P<0.05);治疗组治疗前后骨密度没有统计学差异(P>0.05);对照组治疗前后的骨密度亦没有统计学差别(P>0.05);而治疗组与对照组治疗前后的骨密度没有明显差别,二者没有统计学差异(P>0.05)。结论通过骨痿方对老年维吾尔族女性骨代谢指标影响的临床研究,表明骨痿方可以很好的改善老年维吾尔族女性骨代谢指标,疗效优于对照组,但对于骨密度的改善,与对照组同样,骨密度没有明显改善。
Objective To study the effect of traditional Chinese medicine “Gushengfang” on the treatment of Uyghur female, spleen and kidney deficiency and blood stasis type senile osteoporosis in Xinjiang, and to observe the changes of biochemical bone specific alkaline phosphatase (BAP) Changes in tartrate-resistant acid phosphatase (TRACP 5b). Methods Sixty patients with diagnostic criteria were collected. According to the random number table, 30 patients in the treatment group and 30 patients in the control group were compared. BMD, BAP, Changes in tartrate-resistant acid phosphatase (TRACP5b). Results The statistical results showed that there was no significant difference between the treatment group and the control group (P = 0.49> 0.05), but there was a significant difference between the two groups (P = 0.02 <0.05). The cure rate and total effective rate of the treatment group were better than those of the control group (P <0.05). There was no significant difference in BMD before and after treatment in the treatment group (P> 0.05) (P> 0.05). There was no significant difference in BMD between the treatment group and the control group before and after treatment (P> 0.05). Conclusions The clinical study of Gushengfang Prescription on the bone metabolic index of elderly Uygur women shows that Gushengfang Prescription can improve the bone metabolic index of the elderly Uighur female well, and the curative effect is better than that of the control group. However, compared with the control group, Similarly, there was no significant improvement in BMD.